CAMBRIDGE, Mass., Jun 23, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).
CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for
CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will
<i><b>-Registration program to evaluate improvements in lung function
(FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR
activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis
patients with the G551D mutation and to provide first evaluation of
activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement
in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>
<i>-Over 3 million Americans have chronic hepatitis C -</i>
-<i>Baby boomers account for 2 of every 3 cases of hepatitis C virus and
vast majority unaware they have this chronic disease </i>-
-<i>Cost burden of hepatitis C to Medicare projected to increase 500% as
baby boomers with HCV age into severe complications of liver disease-</i>
CAMBRIDGE, Mass., May 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2009 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan
CAMBRIDGE, Mass., May 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, 2009 at 8:40 a.m. EDT; at R. W.
CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of
<i><b>-Addition of telaprevir to standard HCV therapies significantly
improved rates of sustained viral response in half the time of current
treatments-</b></i><i><b>-SVR rates in Phase 2b studies of up to 69% with 24 weeks of
telaprevir-based treatment-</b></i><i><b>-Phase 3 program ongoing in more than 2,200 patients-</b></i>
<i>- Superior SVR rates with telaprevir across all HCV genotype 1
non-responders and relapser patients and patients with cirrhosis - up to
76% in prior relapsers -</i><i>- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens
compared to 14% in the 48-week control arm</i><i>-</i><i>- Treatment-failure patient population represents the greatest unmet
medical need in HCV -</i>
<i>-PROVE 3 results to be presented at late breaker session on Saturday,
April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate
activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid,
powerful antiviral activity with favorable safety and tolerability
profile-</i>
<i>- Telaprevir registration program on track; VCH-222 enters
multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D
mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash
equivalents and marketable securities-</i>
CAMBRIDGE, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2009 financial results on Thursday, April 16, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Mar 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at Citi's 4 th Annual Biotech Day on Wednesday, April 1, 2009 at 2:40 p.m. EDT and at the Canaccord Adams Hepatitis C Conference on
<i><b>- Primary endpoints of safety and tolerability to be evaluated in
Phase 2a clinical trial -</b></i><i><b>- Measurements of CFTR function to be assessed as secondary
endpoints -</b></i><i><b>- Trial to enroll approximately 90 patients with the F508del CFTR
mutation -</b></i>
<i><b>- PROVE 3 SVR results accepted as late-breaker oral presentation -</b></i><i><b>- First clinical results for VCH-222 in HCV patients accepted as
poster presentation -</b></i>
CAMBRIDGE, Mass., Mar 13, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen & Company 29 th Annual Health Care Conference on Tuesday, March 17, 2009 at 2:25 p.m. EDT.
<i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock
transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have
demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009
start -</i>
CAMBRIDGE, Mass., Feb 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
CAMBRIDGE, Mass., Feb 09, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated : Telaprevir dosing in Phase 3 ADVANCE clinical trial complete and Phase 3 REALIZE clinical trial completes enrollment VX-770 expected to commence registration program for cystic fibrosis in first half of 2009
CAMBRIDGE, Mass., Feb 05, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated President, CEO, and Founder Joshua Boger, Ph.D. Will Retire in May 2009 Vertex Board Member Matthew Emmens Appointed President and Will Transition to President, CEO and Chairman in May 2009 The board of directors
CAMBRIDGE, Mass., Feb 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its 2008 financial results on Monday, February 9, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
- Broad telaprevir registration program for treatment-naive and <br> treatment-failure HCV patients nears enrollment completion -- Vertex expects to initiate VX-770 registration program in cystic <br> fibrosis -- Vertex ends 2008 with approximately $830 million in cash, cash <br> equivalents & marketable securities -
CAMBRIDGE, Mass., Jan 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 27 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m. PST (4:30 p.m. EST).
CAMBRIDGE, Mass., Nov 26, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Piper Jaffray 20 th Annual Health Care Conference on Tuesday, December 2, 2008 at 10:30 a.m.
CAMBRIDGE, Mass., Nov 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 19, 2008 at 2:30 p.m.
CAMBRIDGE, Mass., Nov 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11, 2008 and at the Credit Suisse 2008 Healthcare Conference on Thursday,
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration PROVE 2 final results confirm 69% SVR in HCV treatment-naïve patients with 24-week
<B><P>-- Phase 3 ADVANCE study of telaprevir in HCV completes enrollment --<br>
-- Registration program for VX-770 in cystic fibrosis being discussed with global authorities --<br>
-- As of September 30, 2008, Vertex had $920 million of cash, cash equivalents and marketable securities--</P></B>
<ul><li>VX-770 was well-tolerated when dosed as 150 mg and 250 mg twice daily for 28 days</li><li>VX-770 resulted in a significant increase in FEV1, and significant changes in sweat chloride and nasal potential difference, important markers of CFTR function</li>
<li>Researchers to present 28-day results at the North American Cystic Fibrosis Conference on October 23</li></ul>
CAMBRIDGE, Mass., Oct 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2008 financial results on Monday, October 27, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Oct 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 9:30 a.m. EDT.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - News) today announced that key data on sustained viral response (SVR) rates in both treatment-naïve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens
CAMBRIDGE, Mass., Sep 24, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology. The title of the abstract is "Phase 2 Study of Telaprevir Administered q8h or
CAMBRIDGE, Mass., Sep 22, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter has exercised in full its option to purchase 1,125,000 shares of common stock at a public offering price of $25.50 per share.
CAMBRIDGE, Mass., Sep 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the UBS 2008 Global Life Sciences Conference on Wednesday, September 24, 2008 at 10:00 a.m. EDT.
CAMBRIDGE, Mass., Sep 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in
CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
CAMBRIDGE, Mass., Sep 04, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. EDT and at the Morgan Stanley Global Healthcare Unplugged
CAMBRIDGE, Mass., Aug 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Thomas Weisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 at 8:00 a.m. EDT.
First HCV protease inhibitor in pivotal trial for this difficult<br> to treat patient population<br><br> Trial to enroll all major treatment-failure patient groups,<br> including null responders, partial responders and relapsers<br><br> Two telaprevir registration programs to address significant unmet<br> need in treatment-naive and treatment-failure patients
CAMBRIDGE, Mass., Aug 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday, August 13, 2008 at 8:30 a.m. EDT.
CAMBRIDGE, Mass., Aug 05, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference on Wednesday, August 6, 2008 at 9:00 a.m. EDT.
-- Treatment-failure data and treatment-naive data strengthen<br> telaprevir's potential profile and highlight broad opportunity<br> in treatment of chronic hepatitis C virus (HCV) infection<br><br> -- VX-770, for cystic fibrosis (CF), completes enrollment for<br> 28-day Phase 2a study; 2009 targeted for initiation of<br> registration studies, pending 28-day study results
CAMBRIDGE, Mass., Jul 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has
Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&D efforts to support new Huntington's disease
